期刊文献+

卵巢上皮性癌组织中GRIM-19蛋白的表达及其临床意义 被引量:4

Expression and clinical significance of GRIM-19 in epithelial ovarian carcinoma
原文传递
导出
摘要 目的探讨细胞凋亡相关基因19(GRIM-19)蛋白在卵巢上皮性癌(卵巢癌)组织中的表达及其与卵巢癌患者临床病理指标和预后的关系。方法收集2000年1月-2006年12月在浙江大学医学院附属妇产科医院手术切除的138份卵巢癌、101份卵巢良性上皮性肿瘤和46份正常卵巢组织标本,采用免疫组化法检测其GRIM-19蛋白的表达水平。并采用Mann—WhitenyU和Kruskal—WallisH检验进行非参数分析,比较不同临床病理指标的卵巢癌组织中GRIM-19蛋白的表达水平;采用Kaplan—Meier和log—rank检验进行单因素生存分析,比较不同GRIM-19蛋白表达水平(分为阴性、弱阳性、中等阳性、强阳性组)的卵巢癌患者的预后;采用多因素Cox回归模型,分析影响卵巢癌患者预后的因素。结果免疫组化法检测显示,卵巢癌、卵巢良性上皮性肿瘤、正常卵巢组织中GRIM-19蛋白的表达水平分别为(3.4±2.0)、(4.7±2.9)和(7.5±2.2)分,两两比较,差异均有统计学意义(P〈0.01);3者间比较,差异也有统计学意义(P〈0.01)。非参数分析显示,GRIM-19蛋白的表达水平与卵巢癌患者的腹水量明显相关(P=0.043),而与卵巢癌患者的年龄、血清CA125水平、病理分化程度、病理类型、手术病理分期、淋巴结转移、原发肿瘤最大直径、术后残留灶直径无关(P〉0.05)。GRIM-19蛋白表达阴性、弱阳性、中等阳性、强阳性组卵巢癌患者分别为38、77、21、2例,单因素生存分析显示,4组间总生存时间比较,差异有统计学意义(P=0.002);4组问无瘤生存时间比较,差异也有统计学意义(P=0.008)。多因素Cox回归模型分析显示,GRIM-19蛋白表达水平(P=0.001)、手术病理分期(P=0.001)、腹水量(P=0.023)和原发肿瘤最大直径(P=0.044)是影响卵巢癌患者预后的独立因素。结论GRIM-19蛋白在卵巢癌组织中的表达明显下降,提示GRIM-19可能是一种新的抑癌基因;GRIM-19蛋白的表达水平是影响卵巢癌患者预后的独立因素,提示其对卵巢癌患者的预后可能有预测价值。 Objective To investigate the expression and clinicopathological features of gene associated with retinoid-interferon mortality-19 ( GRIM-19 ) in epithelial ovarian carcinoma. Methods The expression of GRIM-19 gene in tissues from 138 cases of epithelial ovarian carcinoma, 102 cases of benign ovarian epithelial tumor and 46 cases of normal ovarian tissues were detected by Immunohistochemistry and Western blot methods. Assembled clinical survival data were analyzed with Kaplan-Meier and Cox regression models. Results The expression level of GRIM-19 in epithelial ovarian carcinoma (3.4 + 2. 0) was lower than that in benign ovarian tumor tissues ( 4. 7 _+ 2. 9 ) and that in normal ovarian tissues ( 7.5 -+ 2. 2 ; P 〈 0. 01 ). The level of GRIM-19 expression was related to the survival time of epithelial ovarian carcinoma patients by Kaplan-Meier analysis ( P = 0. 002). The shorter survival time of epithelial ovarian carcinoma patients was significantly associated with the level of GRIM-19 expression (P = 0. 001 ), clinical stage (P =0. 001 ) , volume of ascites (P = 0. 023 ) and the largest diameter of the primary tumor lesion (P--0. 044 ) by Cox regression models. Conclusions The low expression of GRIM-19 in the epithelial ovarian eareinoma suggests that GRIM-19 may be a key gene involved in its carcinogenesis. The expression level of GRIM-19 may be also an independent prognostic faetor for epithelial ovarian carcinoma patients.
出处 《中华妇产科杂志》 CAS CSCD 北大核心 2012年第10期751-755,共5页 Chinese Journal of Obstetrics and Gynecology
基金 浙江省医药卫生科技计划(2010KYA130)
关键词 卵巢肿瘤 免疫组织化学 预后 NADH NADPH氧化还原酶类 凋亡调节蛋白质 Ovarian neoplasms Immunohistoehemistry Prognosis NADH, NADPH oxidoreduetases Apoptosis regulatory proteins
  • 相关文献

参考文献2

二级参考文献20

  • 1Seo T, Lee D, Shim YS, et al. Viral interferon regulatory factor I of Kaposi's sarcoma-associated herpesvirus interacts with a cell death regulator, GRIM-19, and inhibits interferon/retinoic acid-induced cell death[ J]. J Virol, 2002,76( 17 ) :8797-8807.
  • 2Lufei C, Ma J, Huang G, et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction [ J]. EMBO J, 2003,22(6) :1325-1335.
  • 3Timofeeva OA, Gaponenko V, Lockett SJ, et al. Rationally designed inhibitors identify STA33 N-domain as a promising anticancer drug target[ J]. ACS Chem Biol, 2007,2(12) :799-809.
  • 4Gamero AM, Young HA, Wiltrout RH. Inactivation of Star3 in tumor cells: releasing a brake on immune responses against cancer [ J ] ? Cancer Cell, 2004,5 ( 2 ) : 111-112.
  • 5Chen CL, Hsieh FC, Lieblein JC, et al. Stat3 activation in human endometrial and cervical cancers [ J ]. Br J Cancer, 2007,96 (4) : 591-599.
  • 6Bromberg J F,Wrzeszczynska M H,Devgan G,et al.Stat3 as an oncogene[J].Cell,1999,98(3):295-303.
  • 7David M,Petricoin E 3rd,Benjamin C,et al.Requirement for MAP kinase (ERK2) activity in interfereon alpha-and interfereon beta-stimulated gene expression through STAT proteins[see comments][J].Science,1995,269(5231):1721-1723.
  • 8Wen Z,Zhong Z,Darnell J E Jr.Maximal activation of transcription by Stall and Stat3 requires both tyrosine and serine phosphorylalion[J].Cell,1995,82(2):241-250.
  • 9Kojima H,Nakajima K,Hirano T.IL-6-inducible complexes on an IL-6 response element of the junB promoter contain Stat3 and 36kDa CRE-like site binding protein (s)[J].Oncogene,1996,12(3):547-554.
  • 10Sasse J,Hemmann U,Schwartz C,et al.Mutational analysis of acute-phase response factor/Stat3 activation and dimerization[J].Mol Cell Biol,1997,17(8):4677-4686.

共引文献42

同被引文献34

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部